Home » Shire’s Gaucher Drug Has Edge Over Rival in Trial
Shire’s Gaucher Drug Has Edge Over Rival in Trial
Shire’s Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi’s Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.
Reuters
Reuters
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May